Impact of Hospital Volume on Clinical Outcomes after Aortoiliac Stenting in Patients with Peripheral Artery Disease

Osamu Iida¹, Mitsuyoshi Takahara², Yasutaka Yamauchi³, Yoshiaki Shintani⁴, Teruyasu Sugano⁵, Yoshito Yamamoto⁶, Daizo Kawasaki⁷, Hiroyoshi Yokoï⁸, Akira Miyamoto⁹, Toshiaki Mano¹ and Masato Nakamura³, on behalf of the OMOTENASHI investigators

¹Cardiovascular Center, Kansai Rosai Hospital, Hyogo, Japan
²Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
³Cardiovascular Center, Takatsu General Hospital, Kawasaki, Kanagawa, Japan
⁴Department of Cardiology, Shin-Koga Hospital, Fukuoka, Japan
⁵Department of Cardiovascular Medicine, Yokohama City University Hospital, Kanagawa, Japan
⁶Department of Cardiovascular Medicine, Iwaki Kyoritsu General Hospital, Fukushima, Japan
⁷Cardiovascular Division, Department of Internal Medicine, Morinomiya Hospital, Osaka, Japan
⁸Cardiovascular Center, Fukuoka Sanno Hospital, Fukuoka, Japan
⁹Division of Cardiovascular Medicine, Toho University, Ohashi Medical Center, Tokyo, Japan

**Aim:** To investigate the impact of institutional volume on clinical outcomes after aortoiliac (AI) stenting in patients with symptomatic peripheral artery disease (PAD).

**Methods:** We analyzed the clinical database from the Observational prospective Multicenter registry study on the Outcomes of peripheral arTERial disease patieNts treated by AngioPlasty tHerapy in the aortoIliac artery (OMOTENASHI) registry. The volume of each institution was evaluated as the number of endovascular therapy (EVT) procedures performed in 2 years (2014–2015). High-volume centers were defined as being in the highest tertile of the procedural volume (≥ 611 EVT procedures in 2 years). Clinical outcomes, treatment strategies, and endovascular procedures were compared between high- and low-volume centers using a propensity score matching.

**Results:** The propensity score matching extracted 236 pairs of patients (as many patients treated at high-volume centers and 519 patients treated at low-volume centers), with no remarkable intergroup differences in the baseline characteristics. Patients treated at high-volume hospitals had a significantly lower 12-month restenosis rate than that of patients treated at low-volume hospitals (6.5% vs. 15.8%, *P* = 0.032), although comparable outcomes between the two groups included the technical success rate (99.6% vs. 99.8%, *P* = 0.58) and the rate of 30-day major adverse events (0.4% vs. 0.8%, *P* = 0.59).

**Conclusion:** Institutional volume was associated with the 12-month restenosis rate after AI stenting for PAD, although comparable perioperative outcomes were also observed between high-volume and low-volume hospitals.

**Key words:** Endovascular treatment/therapy, Aortoiliac lesion, Institutional volume, Restenosis

Introduction

Stent-supported endovascular therapy (EVT) for aortoiliac (AI) lesions is now regarded as the first-line treatment with acceptable efficacy and safety and is widely applied to patients with peripheral artery disease (PAD) in real-world clinical practice. Previous literature reported the association of the institutional volume with in-hospital outcomes in AI endovascular revascularization. However, with the
recent development of dedicated devices and an accumulation of experience in endovascular field, perioperative outcome has been dramatically improved and the incidence of in-hospital adverse events has been greatly declined. Recently, the incidence of in-hospital outcomes after EVT for AI lesions has become far lower than that after surgical reconstruction, almost reaching a clinically negligible level. Given these situations, the next question raised in clinical practice is the volume–outcome association regarding a long-term outcome, i.e., patency after revascularization. However, whether the institutional volume is associated with primary patency after AI stenting in clinical practice remained so far unknown. The aim of the current study is to reveal the impact of institutional volume on clinical outcomes after AI stenting for patients with symptomatic PAD in today’s real-world settings.

Methods

We analyzed a clinical database from the Observational prospective Multicenter registry study on the Outcomes of peripheral arTerial disease patiEnts treated by Angioplasty tHerapy in the aortolilac artery (OMOTENASHI) registry. The OMOTENASHI study was conducted at 64 centers in Japan to register patients with symptomatic PAD (Rutherford category 2, 3, or 4) who were undergoing EVT for iliac lesions between January 2014 and April 2016. The institutional volume of each center was evaluated as the number of EVT procedures performed during the 2 years between 2014 and 2015. The data on the institutional volume were available in 61 of the 64 centers, at which 884 patients were registered with eligibility for the study. Of the 884 patients, 803 underwent self-expandable stent implantation. As described below, we conducted a propensity score matching. To keep subjects otherwise independent of one another during the analysis, a unilateral limb was randomly selected as the representative limb in patients with bilateral iliac lesions. High-volume centers were defined as being in the highest tertile of procedural volume (≥ 611 EVT procedures per 2 years). The tertile was based on the number of the registered patients, rather than that of the participating institutions. Consequently, 281 of the 803 patients (35%) were categorized as those treated at a high-volume center, whereas the remaining 522 patients (65%) were categorized as those treated at a low-volume center. Out of the 61 institutions, 11 institutions performed ≥ 611 EVT procedures (median: 1045 procedures; interquartile range: 838–1131 procedures) between 2014 and 2015, whereas the remaining 50 institutions performed < 611 procedures (median: 264 procedures; interquartile range: 212–381 procedures). Clinical outcomes, treatment strategies, and endovascular procedures were compared between high- and low-volume centers.

Endpoints

The primary perioperative endpoint was 30-day major adverse events (MAE), which included all-cause death, myocardial infarction, stroke, and target vessel revascularization (TVR). The primary endpoint was 12-month restenosis, defined as ≥ 50% stenosis on computed tomography or angiography, or a peak systolic velocity ratio ≥ 2.5 on duplex ultrasound. The requirement for TVR, which was defined as any re-intervention, including surgical or percutaneous approach for targeted vessel, was also included as restenosis. Restenosis was assessed for iliac territories and did not include femoropopliteal lesions.

Secondary endpoints included initial technical success, defined as angiographic residual stenosis < 30% after balloon dilatation or stent implantation, and 12-month TVR. TVR and MAE were determined by an independent clinical events committee (CEC) whose members were not directly involved in this study and had relevant expert knowledge. The CEC assessed TVR through an analysis of angiographic images.

Statistical Analysis

The baseline characteristics data are presented as the mean ± standard deviation (SD) for continuous variables and as the frequency (percentage) for categorical variables, if not otherwise mentioned. P < 0.05 was considered significant. The differences in baseline characteristics between groups were crudely tested by Welch’s t-test for continuous variables, Fisher’s exact test for dichotomous variables, and Mann–Whitney U test for ordinal categorical variables.

When treatment strategies, endovascular procedures, and clinical outcomes were compared between the patients treated at high-volume centers and those treated at low-volume centers, propensity score matching was performed to minimize the intergroup differences in baseline characteristics. The propensity score was developed using a logistic regression model. The following explanatory variables were included in the model: age, sex, body mass index, smoking, hypertension, dyslipidemia, diabetes mellitus, regular dialysis, myocardial infarction, ischemic stroke, medication use, the Rutherford classification, ankle–brachial pressure index, TASC II classification, chronic total occlusion, calcification, lesion localization, total stent length, mean stent diameter, femoropopliteal lesion,
and contralateral iliac lesion warranting revascularization. Matching was performed on the logit of the propensity score within the range of 0.2 SD of the logit of the propensity score. To maximize the statistical power and to detect intergroup prognostic differences, we extracted as many matched patients treated at a low-volume center to those treated at a high-volume center as possible. After matching, the intergroup differences were analyzed with stratification by matched pairs, and weighted descriptive statistics are reported. The difference in binary and continuous outcomes was assessed using a generalized linear mixed model with a logit-link function and a linear mixed model for continuous outcomes, in which a matched pair was treated as a cluster. For missing data, multiple imputation (50 times) was adopted. Time-to-event outcomes were analyzed by the Kaplan–Meier method and log-rank test. Point estimates are reported with their 95% confidence intervals. The estimation of odds ratios for 12-month restenosis (loss of patency) and the assessment of interaction effects were performed with stratification by quintiles of propensity score using a generalized linear mixed model with a logit-link function. All statistical analyses were performed with R version 3.1.0 (R Development Core Team, Vienna, Austria).

Results

The baseline characteristics are shown in Table 1. Patients treated at high-volume centers had a higher prevalence of regular dialysis (17.1% vs. 9.2%), arterial calcification (85.7% vs. 77.4%), common iliac artery lesions (73.7% vs. 62.5%), and contralateral iliac lesions warranting revascularization (35.6% vs. 25.1%), but they had a lower prevalence of male sex (79.7% vs. 85.4%), dyslipidemia (77.2% vs. 84.3%), thienopyridine use (63.0% vs. 79.1%), dual antiplatelet therapy (45.6% vs. 55.7%), statin use (42.0% vs. 55.6%), Rutherford category 2 (32.7% vs. 46.4%), and chronic total occlusion (28.8% vs. 36.8%). The mean diameter of implanted stents was significantly larger in patients treated at high-volume centers (9.4 ± 1.3 vs. 9.1 ± 1.2 mm). Data on 30-day MAE were available in all 803 patients (100%), whereas data on 12-month restenosis were available in 458 patients (57.0%).

Propensity score matching extracted 236 pairs (as many patients treated at high-volume centers and 519 patients treated at low-volume centers), with no remarkable intergroup differences in baseline characteristics (Table 1). Table 2 summarizes the intergroup differences in endovascular strategies and clinical outcomes. During EVT, the rates of using a 0.035-inch wire and a hemostasis device were significantly more frequent at high-volume centers than at low-volume centers (44.2% [37.9 to 50.6%] vs. 19.7% [16.5 to 23.3%] and 52.1% [45.7 to 58.4%] vs. 41.8% [37.6 to 46.1%], respectively), whereas preballooning and intravascular ultrasound (IVUS) use were less frequent (59.7% [53.4 to 65.8%] vs. 80.0% [76.3 to 83.2%] and 52.5% [46.2 to 58.8%] vs. 77.5% [73.7 to 80.8%], respectively). A significantly larger volume of contrast agent was used at high-volume centers (108 [101 to 115] vs. 96 [91 to 101] ml), whereas the procedure time was ≤ 1 hour in more cases (68.6% [62.4 to 74.2%] vs. 50.5% [46.2 to 54.8%]), and the radiation time was shorter (27 [23 to 30] vs. 32 [29 to 34] min) at high-volume centers than at low-volume centers. The risk of 30-day MAE was not significantly different between the two groups (0.4% [0.1 to 2.9%] vs. 0.8% [0.3 to 2.0%], P=0.59), whereas 12-month restenosis was significantly less prevalent in patients treated at high-volume centers (6.5% [2.8 to 14.1%] vs. 15.8% [11.5 to 21.2%], P=0.032, Fig. 1). The association of institutional volume with restenosis risk was not significantly different between the subgroups of the population (Table 3).

Discussion

The current propensity score matching demonstrated that perioperative outcomes, including technical success and 30-day MAE, were not significantly different between high- and low-volume centers, whereas the 12-month restenosis rate was significantly lower at high-volume centers than at low-volume centers.

To date, in the field of percutaneous coronary intervention (PCI), several studies report that treatment in institutions and by operators with high case volumes favorably impacts long-term adverse outcomes, representing the volume–outcome relationship. Accordingly, current clinical guidelines for coronary intervention recommend institutions and operators to experience > 400 PCIs per year and ≥ 75 PCIs per year, respectively. The latest clinical competence statement has relaxed the minimum requirements for PCI performance (> 200 PCI procedures per year for institutions and ≥ 50 PCI procedures per year for operators) to reflect the recent decline in the number of PCI procedures performed.

In the field of peripheral intervention, previous studies reported a volume–outcome relationship regarding perioperative outcomes. Presumably based on those reports, clinical guidelines for selection of revascularization in complex AI lesions recommend...
Table 1. Baseline characteristics of the study population before and after matching

| Variable                              | Overall population (before matching) | Matched population |
|---------------------------------------|-------------------------------------|--------------------|
|                                       | Patients treated at higher-volume centers | Patients treated at lower-volume centers | Standard difference (%) | P value | Patients treated at higher-volume centers | Patients treated at lower-volume centers | Standard difference (%) |
|                                       | (n = 281) | (n = 522) | | | (n = 236) | (n = 519) | |
| Age (years)                           | 73 ± 9   | 73 ± 9   | 1.5 | 0.84 | 73 ± 9   | 73 ± 9   | 0.7 |
| Male sex                              | 79.7%    | 85.4%    | 15.1 | 0.046 | 81.4%    | 81.7%    | 0.8 |
| Body mass index (kg/m²)               | 22.7 ± 3.4 | 22.5 ± 3.3 | 5.7 | 0.44 | 22.7 ± 3.3 | 22.7 ± 3.3 | 0.2 |
| Current smoking                       | 34.2%    | 36.0%    | 3.9 | 0.64 | 36.0%    | 36.0%    | 0.1 |
| Hypertension                          | 93.6%    | 94.6%    | 4.4 | 0.53 | 93.6%    | 94.0%    | 1.7 |
| Dyslipidemia                          | 77.2%    | 84.3%    | 18.0 | 0.016 | 78.0%    | 78.6%    | 1.5 |
| Diabetes mellitus                     | 45.9%    | 49.6%    | 7.4 | 0.34 | 46.2%    | 46.1%    | 0.3 |
| Regular dialysis                      | 17.1%    | 9.2%     | 23.5 | 0.001 | 15.7%    | 13.7%    | 5.5 |
| Myocardial infarction                 | 12.8%    | 13.0%    | 0.6 | 1.00 | 13.1%    | 12.5%    | 1.8 |
| Ischemic stroke                       | 13.2%    | 16.9%    | 10.3 | 0.19 | 12.7%    | 13.2%    | 1.4 |
| Aspirin use                           | 74.0%    | 74.3%    | 0.7 | 0.93 | 75.8%    | 74.6%    | 3.0 |
| Thienopyridine use                    | 63.0%    | 79.1%    | 36.1 | < 0.001 | 67.4%    | 70.0%    | 5.6 |
| Dual antiplatelet therapy             | 45.6%    | 55.7%    | 20.5 | 0.006 | 47.9%    | 49.8%    | 3.8 |
| Anticoagulant use                     | 7.1%     | 8.8%     | 6.3 | 0.50 | 7.6%     | 7.6%     | 0.2 |
| Cilostazol use                        | 27.0%    | 24.1%    | 6.7 | 0.39 | 28.0%    | 25.5%    | 5.6 |
| Statin use                            | 42.0%    | 55.6%    | 27.4 | < 0.001 | 43.2%    | 46.9%    | 4.8 |
| Rutherford classification             |                     |                     |       |       |                     |                     |       |
| Category 2                            | 32.7%    | 46.4%    | 28.1 | 0.002 | 36.9%    | 34.2%    | 5.5 |
| Category 3                            | 60.9%    | 45.8%    | 30.6 | 0.58 | 56.8%    | 58.3%    | 3.2 |
| Category 4                            | 6.4%     | 7.9%     | 5.6 | 0.64 | 6.4%     | 7.4%     | 4.2 |
| Ankle-brachial index (missing data)   | 0.68 ± 0.23 | 0.66 ± 0.20 | 9.8 | 0.20 | 0.67 ± 0.22 | 0.66 ± 0.20 | 4.9 |
| TASC II classification                |                     |                     |        |       |                     |                     |       |
| Class A                               | 47.7%    | 43.7%    | 8.1 | 1.4% | 49.2%    | 46.1%    | 6.0 |
| Class B                               | 21.7%    | 23.4%    | 4.0 | 0.4% | 22.5%    | 23.3%    | 2.1 |
| Class C                               | 9.6%     | 14.4%    | 14.7 | 22.5% | 10.0%    | 23.3%    | 5.8 |
| Class D                               | 21.0%    | 18.6%    | 6.1 | 19.9% | 20.5%    | 5.8 |
| Chronic total occlusion               | 29.2%    | 38.3%    | 19.4 | 0.011 | 30.1%    | 33.6%    | 7.5 |
| Calcification                         | 87.1%    | 77.1%    | 26.5 | 0.001 | 86.8%    | 86.5%    | 0.3 |
| (missing data)                        | 0.4%     | 1.3%     | 10.8 | 0.27 | 0.4%     | 0.7%     | 3.6 |
| Common iliac artery lesion (missing data) | 74.6% | 62.5%    | 26.5 | 0.001 | 72.0%    | 71.0%    | 2.3 |
| External iliac artery lesion (missing data) | 0.4% | 0.0%     | 8.5 | 0.35 | 0.0%     | 0.0%     | 0.9 |
| Ostium lesion                         | 41.6%    | 36.6%    | 10.4 | 0.17 | 39.4%    | 41.4%    | 4.1 |
| Total stent length (mm)               | 83.4 ± 46.2 | 80.2 ± 45.6 | 6.8 | 0.36 | 82.1 ± 45.1 | 81.7 ± 46.5 | 0.9 |
| Mean stent diameter (mm)              | 9.5 ± 1.3 | 9.1 ± 1.2 | 29.5 | < 0.001 | 9.4 ± 1.4 | 9.4 ± 1.3 | 0.6 |
| Femoropopliteal lesion (missing data) | 37.8%    | 36.7%    | 2.3 | 0.81 | 37.9%    | 35.9%    | 4.2 |
| Infrapopliteal revascularization      | 17.1%    | 2.3%     | 51.6 | < 0.001 | 7.2%     | 5.1%     | 8.8 |
| Contralateral iliac revascularization | 0.4%     | 0.4%     | 0.4 | 1.00 | 0.4%     | 0.3%     | 2.7 |

Note: The table includes a comparison of baseline characteristics between patients treated at higher-volume and lower-volume centers before and after matching. The differences are statistically significant as indicated by the P values.
that EVT be performed by an experienced team. However, recent distinct advancements in endovascular devices and techniques and perioperative adverse events were substantially decreased in incidence (8, 9, 10, 11). The current study reveals that the incidence rate of 30-day MAE was very low even in low-volume centers. Furthermore, although this registry included some challenging lesions (e.g., 20% were TASC II class D lesion and approximately 30% were CTO lesions), both classes of centers achieved an almost 100% technical success rate, which was much higher than that reported in previous studies (11). This range may be the result of recent developments in devices (CTO-specific guidewire) and technical procedures (bilateral two-way approach [bilateral femoral or brachiofemoral approach]) for achieving standardized intervention. On the contrary, procedural time and radiation time were longer at low-volume centers than at high-volume centers, whereas low-volume centers used IVUS more frequently, with a lower amount of contrast agent used. These findings indicate potential technical and procedural differences between low- and high-volume centers, which may yield inter-center difference in medical resource use, although low-volume centers apparently achieved similar short-term outcomes compared with high-volume centers.

Table 2. Endovascular procedures and clinical outcomes (after matching)

| Endovascular treatment                          | Patients treated at higher-volume centers | Patients treated at lower-volume centers | P value |
|------------------------------------------------|-------------------------------------------|-----------------------------------------|---------|
| 0.035-inch wire first selected                 | 44.2% [37.9 to 50.6%]                     | 19.7% [16.5 to 23.3%]                   | <0.001  |
| 0.035-inch wire finally used                   | 36.9% [31.0 to 43.3%]                     | 16.8% [13.8 to 20.2%]                   | <0.001  |
| Pre-ballooning                                  | 59.7% [53.4 to 65.8%]                     | 80.0% [76.3 to 83.2%]                   | <0.001  |
| Number of stents used                          | 1.3 [1.2 to 1.3]                          | 1.2 [1.2 to 1.2]                        | 0.22    |
| Intravascular ultrasound use                   | 52.5% [46.2 to 58.8%]                     | 77.5% [73.7 to 80.8%]                   | <0.001  |
| Distal protection                              | 2.1% [0.9 to 5.0%]                        | 3.1% [1.9 to 5.0%]                      | 0.46    |
| Hemostasis device use                          | 52.1% [45.7 to 58.4%]                     | 41.8% [37.6 to 46.1%]                   | 0.008   |
| Procedure time ≤ 1 hour                        | 68.6% [62.4 to 74.2%]                     | 50.5% [46.2 to 54.8%]                   | <0.001  |
| Contrast agent volume (mL)                     | 108 [101 to 115]                          | 96 [91 to 101]                          | 0.010   |
| Radiation time (min)                           | 27 [23 to 30]                             | 32 [29 to 34]                           | 0.019   |
| Postoperative outcomes                         |                                           |                                         |         |
| Technical success                              | 99.6% [97.1 to 99.9%]                     | 99.8% [98.6 to 100.0%]                  | 0.58    |
| 30-day major adverse event                     | 0.4% [0.1 to 2.9%]                        | 0.8% [0.3 to 2.0%]                      | 0.59    |
| 12-month clinical outcomes                     |                                           |                                         |         |
| Restenosis                                     | 6.5% [2.8 to 14.1%]                       | 15.8% [11.5 to 21.2%]                   | 0.032   |
| TVR                                            | 0.5% [0.0 to 1.6%]                        | 2.1% [0.1 to 4.0%]                      | 0.090   |

Fig. 1. Twelve-month restenosis rate between high- and low-volume centers

The incidence of 12-month restenosis was significantly lower in patients treated at high-volume centers (6.5% [2.8 to 14.1%] vs. 15.8% [11.5 to 21.2%], P=0.032).
Another important difference between low- and high-volume centers was the 12-month restenosis rate, which was significantly lower in the high-volume center group than in the low-volume center group. The subsequent interaction analysis confirmed that the superiority was irrelevant to the lesion complexity. Even when population was limited into non-complex AI lesions, 12-month restenosis rate in the low-volume center was still higher than that in the high-volume center. Although the true reasons for this significant difference remained unrevealed, some technical difference may be involved. One speculation regarding the superiority of high-volume centers in primary patency is that endovascular specialty or endovascular-specific skills, which is an unmeasurable parameter, rather than imaging modality or device selection, plays an important role in achieving better long-term outcomes after AI intervention. High-volume centers are expected to be superior in the endovascular technique. The current findings may demonstrate that the clinical guidelines’ recommendation that hospital experience is important in EVT for complex AI lesions is still valid in the current clinical settings. The findings will also suggest the importance of hospital experience even in EVT for non-complex lesions. Our findings indicate that hospital volume may be a practical surrogate of quality for “any” AI endovascular intervention.

The current study has several limitations. First, this study was not a randomized controlled trial. However, propensity score matching based on pro-

### Table 3. Interaction effect on the association of institutional volume with restenosis risk

|                        | Odds ratio of higher-volume centers for 12-month restenosis | P for interaction | Odds ratio of higher-volume centers for 12-month restenosis | P for interaction |
|------------------------|-------------------------------------------------------------|-------------------|-------------------------------------------------------------|-------------------|
| Overall                | 0.46 [0.23 to 0.94]                                         | 0.33              |                                                             | 0.53              |
| Age                    |                                                             |                   |                                                             |                   |
| <75 years              | 0.59 [0.25 to 1.37]                                         | 0.62              | 0.43 [0.21 to 0.92]                                         | 0.33              |
| ≥75 years              | 0.33 [0.11 to 1.00]                                         |                   | 0.85 [0.11 to 6.38]                                         |                   |
| Sex                    |                                                             |                   |                                                             |                   |
| Female                 | 0.66 [0.15 to 2.81]                                         | 0.62              | 0.45 [0.21 to 0.94]                                         | 0.66              |
| Male                   | 0.44 [0.20 to 0.95]                                         |                   | 0.50 [0.14 to 1.74]                                         |                   |
| Body mass index        |                                                             |                   |                                                             |                   |
| <22 kg/m²              | 0.41 [0.15 to 1.15]                                         | 0.90              |                                                             |                   |
| ≥22 kg/m²              | 0.50 [0.20 to 1.27]                                         |                   |                                                             |                   |
| Current smoking        |                                                             |                   |                                                             |                   |
| No                     | 0.38 [0.14 to 1.02]                                         | 0.44              |                                                             | 0.60              |
| Yes                    | 0.61 [0.26 to 1.47]                                         |                   |                                                             |                   |
| Hypertension           |                                                             |                   |                                                             |                   |
| No                     | 0.77 [0.10 to 5.66]                                         | 0.58              |                                                             |                   |
| Yes                    | 0.45 [0.21 to 0.94]                                         |                   |                                                             |                   |
| Dyslipidemia           |                                                             |                   |                                                             |                   |
| No                     | 0.46 [0.12 to 1.72]                                         | 1.00              |                                                             |                   |
| Yes                    | 0.45 [0.19 to 1.04]                                         |                   |                                                             |                   |
| Diabetes mellitus      |                                                             |                   |                                                             |                   |
| No                     | 0.51 [0.20 to 1.29]                                         | 0.84              |                                                             |                   |
| Yes                    | 0.43 [0.16 to 1.16]                                         |                   |                                                             |                   |
| Regular dialysis       |                                                             |                   |                                                             |                   |
| No                     | 0.44 [0.19 to 1.00]                                         | 0.96              |                                                             |                   |
| Yes                    | 0.37 [0.08 to 1.87]                                         |                   |                                                             |                   |
| Myocardial infarction  |                                                             |                   |                                                             |                   |
| No                     | 0.45 [0.20 to 0.99]                                         | 0.70              |                                                             |                   |
| Yes                    | 0.59 [0.15 to 2.31]                                         |                   |                                                             |                   |
| Aspirin use            |                                                             |                   |                                                             |                   |
| No                     | 0.69 [0.19 to 2.48]                                         | 0.49              |                                                             |                   |
| Yes                    | 0.41 [0.18 to 0.90]                                         |                   |                                                             |                   |
| Thienopyridine use     |                                                             |                   |                                                             |                   |
| No                     | 0.62 [0.25 to 1.54]                                         | 0.26              |                                                             |                   |
| Yes                    | 0.28 [0.09 to 0.87]                                         |                   |                                                             |                   |
| Dual antplatelet therapy|                                                             |                   |                                                             |                   |
| No                     | 0.62 [0.27 to 1.42]                                         | 0.19              |                                                             |                   |
| Yes                    | 0.24 [0.07 to 0.86]                                         |                   |                                                             |                   |
| Anticoagulant use      |                                                             |                   |                                                             |                   |
| No                     | 0.46 [0.22 to 0.98]                                         | 0.95              |                                                             |                   |
| Yes                    | 0.44 [0.07 to 3.01]                                         |                   |                                                             |                   |
| Cilostazol use         |                                                             |                   |                                                             |                   |
| No                     | 0.35 [0.14 to 0.83]                                         | 0.16              |                                                             |                   |
| Yes                    | 0.83 [0.29 to 2.37]                                         |                   |                                                             |                   |
| Statin use             |                                                             |                   |                                                             |                   |
| No                     | 0.39 [0.16 to 0.97]                                         | 0.60              |                                                             |                   |
| Yes                    | 0.57 [0.21 to 1.54]                                         |                   |                                                             |                   |
| Rutherford classification|                                                             |                   |                                                             |                   |
| category 2/3            | 0.32 [0.09 to 1.11]                                         | 0.98              |                                                             |                   |
| category 4              | 0.68 [0.26 to 1.78]                                         |                   |                                                             |                   |
| TASC II classification |                                                             |                   |                                                             |                   |
| class A to C            | 0.45 [0.21 to 0.98]                                         | 0.86              |                                                             |                   |
| class D                | 0.50 [0.14 to 1.74]                                         |                   |                                                             |                   |
| Chronic total occlusion|                                                             |                   |                                                             |                   |
| No                     | 0.56 [0.26 to 1.17]                                         | 0.55              |                                                             |                   |
| Yes                    | 0.36 [0.09 to 1.42]                                         |                   |                                                             |                   |
| Total stent length     |                                                             |                   |                                                             |                   |
| <100 mm                | 0.49 [0.22 to 1.11]                                         | 0.84              |                                                             |                   |
| ≥100 mm                | 0.40 [0.13 to 1.26]                                         |                   |                                                             |                   |
| Mean stent diameter    |                                                             |                   |                                                             |                   |
| <9.0 mm                | 0.68 [0.26 to 1.78]                                         | 0.37              |                                                             |                   |
| ≥9.0 mm                | 0.36 [0.13 to 1.00]                                         |                   |                                                             |                   |
| Femoropopliteal lesion |                                                             |                   |                                                             |                   |
| No                     | 0.43 [0.13 to 1.36]                                         | 0.81              |                                                             |                   |
| Yes                    | 0.46 [0.20 to 1.10]                                         |                   |                                                             |                   |
| Contralateral iliac revascularization | No | 0.44 [0.17 to 1.11] | 0.98 | 0.41 [0.15 to 1.14] | 0.79 |
| Yes                    |                                                             |                   |                                                             |                   |
| Stent use              |                                                             |                   |                                                             |                   |
| single                 | 0.45 [0.21 to 0.96]                                         | 0.79              |                                                             |                   |
| multiple               | 0.53 [0.15 to 1.90]                                         |                   |                                                             |                   |
| Intravascular ultrasound use | No | 0.55 [0.20 to 1.54] | 0.66 | 0.42 [0.14 to 1.29] | 0.28 |
| Yes                    |                                                             |                   |                                                             |                   |
| Hemostasis device use  |                                                             |                   |                                                             |                   |
| No                     | 0.41 [0.15 to 1.16]                                         | 0.62              |                                                             |                   |
| Yes                    | 0.57 [0.24 to 1.37]                                         |                   |                                                             |                   |
| Pre-ballooning         |                                                             |                   |                                                             |                   |
| No                     | 0.49 [0.17 to 1.43]                                         | 0.93              |                                                             |                   |
| Yes                    | 0.44 [0.18 to 1.08]                                         |                   |                                                             |                   |
| Procedure time ≤ 1 hour|                                                             |                   |                                                             |                   |
| No                     | 0.53 [0.17 to 1.64]                                         | 0.97              |                                                             |                   |
| Yes                    | 0.52 [0.22 to 1.25]                                         |                   |                                                             |                   |
| Contrast agent         |                                                             |                   |                                                             |                   |
| <100 ml                | 0.48 [0.19 to 1.21]                                         | 0.94              |                                                             |                   |
| ≥100 ml                | 0.42 [0.15 to 1.12]                                         |                   |                                                             |                   |
| Radiation time         |                                                             |                   |                                                             |                   |
| ≤30 min                | 0.68 [0.31 to 1.50]                                         | 0.28              |                                                             |                   |
| ≥30 min                | 0.32 [0.09 to 1.11]                                         |                   |                                                             |                   |
spective collected data was employed to reduce bias as much as possible. In addition, data on 12-month restenosis were available in only about a half of the study population, although we adopted the multiple imputation method to address this issue. Second, detailed information on lesion morphology and procedural information was limited. Third, the assessment for restenosis was not conducted under core laboratory review. Fourth, the data on operator volume and the number of AI EVT procedures at each center were unavailable. We were unable to assess the association between lower operator volume and increased risk of outcomes. Outcomes may be more properly evaluated according to the number of AI EVT procedures at each center, rather than the whole number of EVT procedures. Finally, only patients who underwent EVT using self-expandable stent were analyzed. In clinical practice, stents have several types, which will affect differences in restenosis rate and may likely influence the outcome than the hospital volume. In the current study, patients not treated with self-expandable stent were consequently eliminated to simply evaluate the impact of hospital volume on outcomes.

Conclusion

Hospital volume was associated with a lower risk of 12-month restenosis after AI stent implantation for patients with symptomatic PAD, although low-volume centers achieved comparable technical success and 30-day major adverse events as high-volume centers did.

Funding Source

The current study was approved by the Research Group on endovascular treatment in aortoiliac artery

Disclosures

None.

References

1) Kashyap VS, Pavkov ML, Bena JF, Sarac TP, O’Hara PJ, Lyden SP, Clair DG. The management of severe aortoiliac occlusive disease: endovascular therapy rivals open reconstruction. J Vasc Surg. 2008; 48: 1451-1457
2) Jongkind V, Akkersdijjk GJ, Jeung KK, Wisselink W. A systematic review of endovascular treatment of extensive aortoiliac occlusive disease. J Vasc Surg, 2010; 52: 1376-1383
3) Soga Y, Iida O, Kawasaki D, Yamauchi Y, Suzuki K, Hirano K, Koshida R, Kamoi D, Tazaki J, Higashitani M, Shintani Y, Yamaoka T, Okazaki S, Suematsu N, Tsuchiya T, Miyashita Y, Shinozaki N, Takahashi H; REAL-AI investigators; on behalf of REAL-AI investigators. Contemporary outcomes after endovascular treatment for aorto-iliac artery disease. Circ J, 2012; 76: 2697-2704
4) Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Röther J, Strynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J, 2018; 39: 763-816
5) Yamauchi Y, Takahara M, Shintani Y, Iida O, Sugano T, Yamamoto Y, Kawasaki D, Fujihara M, Hirano K, Yoko H, Miyamoto A, Nakamura M; OMOTENASHI investigators. One-Year Outcomes of Endovascular Therapy for Aortoiliac Lesions. Circ Cardiovasc Interv, 2019 Jan; 12(1): e007441
6) Goka EA, Phillips P, Poku E, Essat M, Woods HB, Walters SJ, Kalententhaler EC, Shackley P, Michaels J. The Relationship between Hospital or Surgeon Volume and Outcomes in Lower Limb Vascular Surgery in the United Kingdom and Europe. Ann Vasc Surg, 2017; 45: 271-286
7) Arora S, Panaich SS, Patel N, Patel N, Lahewala S, Solanki S, Patel P, Patel A, Manvar S, Savani C, Tripathi B, Thakkar B, Jhamnani S, Singh V, Patel P, Patel J, Bhi- mani R, Mohamad T, Remetz MS, Curtis JP, Attaran RR, Grines C, Mena CI, Cleman M, Forrest J, Badheka AO. Impact of Hospital Volume on Outcomes of Lower Extremity Endovascular Interventions (Insightsfrom the Nationwide Inpatient Sample [2006 to 2011]). Am J Cardiol, 2015; 116: 791-800
8) Indes JE, Tuggle CT, Mandawat A, Muhs BE, Sosa JA. Effect of physician and hospital experience on patient outcomes for endovascular treatment of aortoiliac occlusive disease. Arch Surg, 2011; 146: 966-971
9) Dimick JB, Cowan JA Jr, Henke PK, Wainess RM, Pos- ner S, Stanley JC, Upchurch GR Jr. Hospital volume–related differences in aorto-bifemoral bypass operative mortality in the United States. J Vasc Surg, 2003; 37: 970-975
10) Iida O, Soga Y, Takahara M, Yamauchi Y, Suzuki K, Hirano K, Koshida R, Kamoi D, Tazaki J, Higashitani M, Shintani Y, Yamaoka T, Okazaki S, Suematsu N, Tsuchiya T, Miyashita Y, Shinozaki N, Takahashi H, Uematsu M. Perioperative Complications After Aorto-iliac Stenting: Associated Factors and Impact on Follow-up Cardiovascular Prognosis. Eur J Vasc Endovasc Surg, 2014; 47: 131-138
11) Norgren L, Hiatt WR, Dormandy JA, Nehrer MR, Harris KA, Fowkes FG; TASC II Working Group, Bell K, Capor Russo J, Durand-Zaleski I, Komori K, Lammer J, Liapis C,
Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler E 3rd, Rutherford RB, Sheehan P, Sillesen H, Rosenfield K. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg, 2007; 33 Suppl 1: S1-75

12) Fanaroff AC, Zakrotsky P, Wojdyla D, Kaltenbach LA, Sherwood MW, Roe MT, Wang TY, Peterson ED, Gurm HS, Cohen MG, Messenger JC, Rao SV. Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention. Circulation, 2019; 139: 458-472

13) Hannan EL, Wu C, Walford G, King SB 3rd, Holmes DR Jr, Ambrose JA, Sharma S, Katz S, Clark LT, Jones RH. Volume outcome relationships for percutaneous coronary interventions in the stent era. Circulation, 2005; 112: 1171-1179

14) Epstein AJ, Rathore SS, Volpp KG, Krumholz HM. Hospital percutaneous coronary intervention volume and patient mortality, 1998 to 2000: does the evidence support current procedure volume minimums? J Am Coll Cardiol, 2004; 43: 1755-1762

15) Badheka AO, Patel NJ, Grover P, Singh V, Patel N, Arora S, Chothani A, Mehta K, Deshmukh A, Savani GT, Patel A, Panaich SS, Shah N, Rathod A, Brown M, Mohamad T, Tamburino FV, Kar S, Makkar R, O’Neill WW, De Marchena E, Schreiber T, Grines CL, Rihal CS, Cohen MG. Impact of annual operator and institutional volume on percutaneous coronary intervention outcomes: a 5-year United States experience (2005-2009). Circulation, 2014; 130: 1392-1406

16) Lin HC, Lee HC, Chu CH. The volume-outcome relationship of percutaneous coronary intervention: can current procedure volume minimums be applied to a developing country? Am Heart, J2008; 155: 547-552

17) Harold JG, Bass TA, Bashore TM, Brindis RG, Brush JE Jr, Burke JA, Dehmer GJ, Deychak YA, Jneid H, Jollis JG, Landzberg JS, Levine GN, McClurken JB, Messenger JC, Moussa ID, Muhlestein JB, Pomerantz RM, Sanborn TA, Sivaram CA, White CJ, Williams ES. ACCF/AHA/SCAI 2013 update of the clinical competence statement on coronary artery interventional procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (Writing Committee to Revise the 2007 Clinical Competence Statement on Cardiac Interventional Procedures). J Am Coll Cardiol, 2013; 62: 357-396

18) Krankenberg H, Zeller T, Ingwersen M, Schmalstieg J, Gissler HM, Nikol S, Baumgartner I, Diehm N, Nickling E, Müller-Hülsbeck S, Schmiedel R, Torsello G, Hochholzer W, Stelzner C, Brechtel K, Ito W, Kidkutha R, Blessing E, Thieme M, Nakonieczny J, Nolte T, Gareis R, Boden H, Sixt S. Self-Expanding Versus Balloon-Expandable Stents for Iliac Artery Occlusive Disease: The Randomized ICE Trial. J Am Coll Cardiol Intv, 2017; 10: 1694-1704